Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

A phase 3 trial found that Eli Lilly's tirzepatide significantly reduced the risk of progression to Type 2 diabetes in prediabetic adults over a three-year period. Nearly 99% of individuals treated ...

Diabetes and weight-loss drug tirzepatide (Mounjaro, Zepbound) was listed as a contributing factor in the death of a 58-year-old nurse from Scotland who died of multiple organ failure, septic shock, ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

A 58-year-old nurse from Scotland has died after taking two doses of weight-loss drug tirzepatide, also known as Mounjaro or ...

Close behind Novo is Eli Lilly with its own drug, tirzepatide, which is branded as both Mounjaro® and Zepbound®. Because of its dual action ... on PharmiWeb.com is designed to support, not replace, ...

The Impact of New Weight Loss Drugs on Dietetics By Carrie Dennett, MPH, RDN Today’s Dietitian Vol. 26 No. 9 P. 14 What’s changed for weight-inclusive and weight management dietitians?

Powerful weight-loss drugs like Wegovy and Zepbound have driven nearly $1 trillion in market-capitalization gains, with most ...

"When developing this menu, it was important to offer blends with a thoughtful balance of nutrient-dense, high-protein, fiber-rich foods to support satiety and muscle mass. We were also mindful of ...

Eli Lilly and its investors this past week learned a hard lesson: The sky is no longer the limit when it comes to sales of its blockbuster glucagon-like peptide 1 (GLP-1) drugs for diabetes and ...

Zepbound and Mounjaro are regarded as the key drivers of the company’s recent growth. These GLP-1 receptor agonists have demonstrated robust traction in the market. Wall Street analysts opine ...